Healthcare
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses: 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2
About this update from Century Therapeutics, Inc.
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses: Both presentations will highlight CNTY-813, Century's iPSC-derived islet replacement therapy program engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes. EASD 2026 Presentation DetailsTitle: CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC-Derived Islets for Off-the-Shelf Cell TherapiesFormat: Oral PresentationPresenter: Grant Welstead, PhD, SVP, Head of Research, Century TherapeuticsSession: OP 39 – Beta cells on demand: stem cells to beta cell therapyPresentation Number: 225Date/Time: Friday, October 2, 2026, 10:00–11:00 AM CEST, Paris Hall CRC 2026 Presentation DetailsTitle: CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC Beta Islets for Off-the-Shelf Cell TherapiesFormat: Oral PresentationPresenter: Leonardo Velazco-Cruz, PhD, Islet Process ScienceSession: 0300 - ORALS 01: Cell Therapy Science & ClinicalPresentation Number: 341Date/Time: Friday, October 9, 2026, 3:50-4:50 PM EDT, Hall 1 Additional information about the EASD 2026 Annual Meeting is available on the EASD website, and additional information about the CRC 2026 Congress is available on the CRC website. Both presentations will be made available on Century's website following the session on its presentations tab: Science | Century Therapeutics. About CNTY-813CNTY-813 is Century's potential iPSC-derived islet replacement therapy for T1D. CNTY-813 is engineered with Allo-Evasion™ 5.0, Century's proprietary immune evasion technology, which is designed to enable durable engraftment without chronic systemic immunosuppression, the central unresolved limitation of every currently approved or late-stage cell therapy approach to T1D. Preclinical data demonstrated robust glucose-responsive function, favorable pre-clinical safety profile, scalable and reproducible manufacturing, and immune protection under alloimmune pressure. Century is targeting an IND submission for CNTY-813 in the fourth quarter of 2026.
View stock analysis, news, and events for Century Therapeutics, Inc.